Who are PF-06954522 IR (Formulation 1)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pf-07940369, E coli Vaccine 4 Dose B.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pf-06954522-ir-formulation-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

PF-06954522 IR (Formulation 1) — Competitive Intelligence Brief

PF-06954522 IR (Formulation 1) (pf-06954522-ir-formulation-1) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Not available.

marketed Not available Not available Live · refreshed every 30 min

Target snapshot

PF-06954522 IR (Formulation 1) (pf-06954522-ir-formulation-1) — Pfizer Inc..

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
PF-06954522 IR (Formulation 1) TARGET	pf-06954522-ir-formulation-1	Pfizer Inc.	marketed	Not available	Not available
Pf-07940369	pf-07940369	Pfizer Inc.	marketed	Not available	Not available
E coli Vaccine 4 Dose B	e-coli-vaccine-4-dose-b	Pfizer Inc.	marketed	Not available	Not available

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Not available class)

Pfizer Inc. · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PF-06954522 IR (Formulation 1) — Competitive Intelligence Brief. https://druglandscape.com/ci/pf-06954522-ir-formulation-1. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab